SCHEDULE: NEA Amends Arcellx Stake, Details Share Distributions

New Enterprise Associates (NEA) updated its beneficial ownership in Arcellx, Inc., reflecting pro rata share distributions to its partners and subsequent individual sales.

Summary

• New Enterprise Associates (NEA) filed an Amendment No. 4 to its Schedule 13D regarding its beneficial ownership of Arcellx, Inc. Common Stock.
• The filing details changes in ownership structure following pro rata distributions of Arcellx shares by NEA 15, L.P. and NEA Partners 15, L.P. to their respective partners.
• As of August 14, 2025, NEA 15, NEA Partners 15, NEA 15 GP, LLC, Forest Baskett, Anthony A. Florence, Jr., and Mohamad H. Makhzoumi each beneficially own 3,045,262 shares, representing 5.49% of Arcellx's outstanding Common Stock.
• Scott D. Sandell beneficially owns 3,055,360 shares, representing 5.51% of the class, which includes shares held by trusts for which he is trustee.
• The percentages are based on 55,458,912 shares of Common Stock reported by Arcellx, Inc. as outstanding on August 1, 2025.
• Subsequent to the distributions on August 12, 2025, certain individuals and entities, including the Makhzoumi Family Trust, Baskett-McKay Family Trust, Anthony A. Florence, Jr., New Enterprise Associates, LLC, and NEA Investment Holdings CF, LLC, conducted open market sales of Arcellx shares on August 13, 2025, at prices ranging from $67.24 to $72.94 per share.

Sentiment

Score: 6

Explanation: The filing is largely neutral, being a compliance update on beneficial ownership changes due to distributions. While individual partners sold some shares, the primary investor (NEA) maintains a significant stake for investment purposes, and the distributions are a normal part of fund management. The sales are relatively small in the context of total beneficial ownership and do not indicate a negative shift in the core investment thesis by NEA itself.

Positives

• The filing indicates that NEA's acquisition of shares was for investment purposes, suggesting continued belief in Arcellx's long-term prospects.
• The distributions were pro rata, indicating a standard process for fund management rather than a targeted divestment by NEA as an entity.

Negatives

• Individual partners and affiliated entities conducted open market sales of Arcellx shares following the distributions, which could be perceived as a reduction in direct exposure by key individuals.

Risks

• The Reporting Persons may dispose of or acquire additional shares of the Issuer depending on market conditions and their ongoing evaluation of Arcellx's business and prospects, which introduces uncertainty regarding future shareholding levels.

Future Outlook

The Reporting Persons state that they may dispose of or acquire additional shares of Arcellx, Inc. based on market conditions and their ongoing evaluation of the company's business and prospects. They currently have no present plans for extraordinary corporate transactions, changes in management or board, or material changes to Arcellx's capitalization or business structure.

Industry Context

This filing is a routine compliance update for a significant institutional investor (NEA) in a biotechnology company (Arcellx, Inc.). It reflects a common practice for venture capital or private equity firms to distribute shares to their limited partners after a company goes public or reaches a certain stage, allowing partners to realize gains. The subsequent individual sales are typical for partners managing their personal portfolios. This does not necessarily reflect a change in the broader industry trend for biotech investments but rather a specific portfolio management action by NEA.

Comparison to Industry Standards

• This filing is a standard Schedule 13D/A, which is a regulatory requirement when a beneficial ownership threshold is crossed or material changes occur.
• The pro rata distribution of shares to limited partners is a common practice for venture capital funds like New Enterprise Associates (NEA) as part of their fund lifecycle management, allowing their investors to receive direct ownership of portfolio company shares. For example, similar distributions have been observed from other major venture capital firms like Andreessen Horowitz or Sequoia Capital when their portfolio companies achieve liquidity events.
• The subsequent open market sales by individual partners are also standard practice for personal portfolio management.
• There are no specific comparable companies or projects mentioned in the filing to assess performance against.

Legal Proceedings

• None of the Reporting Persons have been convicted in a criminal proceeding or been a party to a civil proceeding ending in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws during the past five years.

Related Party Transactions

• NEA 15, L.P. made a pro rata distribution of 700,000 shares of Common Stock to its general partner (NEA Partners 15, L.P.) and its limited partners for no consideration.
• NEA Partners 15, L.P. made a pro rata distribution of 168,217 shares of Common Stock to its limited partners for no consideration.
• These distributions are internal to the NEA group and its partners.

Stakeholder Impact

• Shareholders: Existing shareholders may observe a slight increase in the float due to the distributions and subsequent sales, potentially impacting liquidity. The continued significant stake by NEA suggests ongoing institutional interest.
• Management: No direct impact on Arcellx's management or operations is indicated by this ownership update.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated.

Next Steps

• The Reporting Persons may dispose of or acquire additional shares of Arcellx, Inc. in the future.

Key Dates

Recommendation

This filing is primarily a compliance update detailing a change in beneficial ownership by a major institutional investor (NEA) due to pro rata distributions to its partners, followed by some individual sales. It does not contain new fundamental information about Arcellx's business operations, financial performance, or strategic direction that would warrant a strong buy or sell recommendation. While the individual sales might create minor selling pressure, the overall beneficial ownership by the NEA group remains substantial, indicating continued investment interest. Therefore, a "hold" recommendation is appropriate as the filing does not present a compelling reason to alter an existing investment position based solely on this information.

Keywords

Arcellx, Inc., NEA, New Enterprise Associates, Schedule 13D, beneficial ownership, common stock, investment, share distribution, SEC filing, biotechnology